David Goldblatt

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2763300/david-goldblatt-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250 papers	11,596 citations	58 h-index	98 g-index
289 ext. papers	14,018 ext. citations	8.2 avg, IF	6.39 L-index

#	Paper	IF	Citations
250	Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Challenge".. *Infection and Immunity*, **2022**, 90, e0084618a	3.7	0
249	Opsonophagocytic Killing Assay to Measure Anti-Group A Streptococcus Antibody Functionality in Human Serum. *Methods in Molecular Biology*, **2022**, 2414, 373-386	1.4	
248	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.. *Nature Cancer*, **2022**,	15.4	5
247	Maintained partial protection against despite B-cell depletion in mice vaccinated with a pneumococcal glycoconjugate vaccine.. *Clinical and Translational Immunology*, **2022**, 11, e1366	6.8	1
246	SARS-CoV-2: from herd immunity to hybrid immunity.. *Nature Reviews Immunology*, **2022**,	36.5	5
245	Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients. *Vaccines*, **2022**, 10, 725	5.3	
244	Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. *Vaccines*, **2022**, 10, 850	5.3	0
243	Towards a population-based threshold of protection for COVID-19 vaccines.. *Vaccine*, **2021**, 40, 306-306	4.1	10
242	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. *Journal of Infectious Diseases*, **2021**,	7	3
241	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature*, **2021**,	50.4	49
240	Cross-sectional prevalence of SARS-CoV-2 antibodies in healthcare workers in paediatric facilities in eight countries. *Journal of Hospital Infection*, **2021**, 110, 60-66	6.9	15
239	Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. *Nature Biotechnology*, **2021**, 39, 989-999	44.5	2
238	Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. *Lancet Infectious Diseases, The*, **2021**, 21, 688-696	25.5	3
237	Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. *Lancet Infectious Diseases, The*, **2021**, 21, 834-846	25.5	11
236	Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *New England Journal of Medicine*, **2021**, 384, 2202-2211	59.2	435
235	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. *Clinical Infectious Diseases*, **2021**,	11.6	11
234	Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1104-1107	11.5	4

233	Preclinical Development of Virulence-attenuated Strains Able to Enhance Protective Immunity against Pneumococcal Infection. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1037-1041	10.2	5
232	Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 604-613	10.2	9
231	Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial. *Lancet HIV,the*, **2021**, 8, e408-e419	7.8	2
230	Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers. *Pediatric Infectious Disease Journal*, **2021**, 40, 937-943	3.4	
229	SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK: A retrospective cohort study. *Lancet Regional Health - Europe, The*, **2021**, 6, 100127		8
228	Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*, **2021**, 39, 4423-4428	4.1	277
227	Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. *Lancet Haematology,the*, **2021**, 8, e542-e544	14.6	37
226	Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2: Findings From an African Birth Cohort. *Pediatric Infectious Disease Journal*, **2021**, 40, e516-e519	3.4	1
225	Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. *Bioanalysis*, **2020**, 12, 1363-1375	2.1	7
224	Vaccine-Induced Th1-Type Response Protects against Invasive Group A Infection in the Absence of Opsonizing Antibodies. *MBio*, **2020**, 11,	7.8	10
223	Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. *Vaccine*, **2020**, 38, 3339-3350	4.1	12
222	A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults. *Pediatric Infectious Disease Journal*, **2020**, 39, 345-351	3.4	8
221	Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. *Vaccine*, **2020**, 38, 399-410	4.1	14
220	Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment. *Clinical Infectious Diseases*, **2020**, 71, 1271-1280	11.6	2
219	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. *Vaccine*, **2020**, 38, 7834-7841	4.1	
218	Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. *Journal of Clinical Virology*, **2020**, 130, 104572	14.5	49
217	Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. *Lancet Infectious Diseases, The*, **2020**, 20, 1426-1436	25.5	3
216	The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to. *Frontiers in Immunology*, **2020**, 11, 611661	8.4	2

215	An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera. *Methods in Molecular Biology*, **2020**, 2136, 323-335	1.4	3
214	Serocorrelates of protection against infant group B streptococcus disease. *Lancet Infectious Diseases, The*, **2019**, 19, e162-e171	25.5	30
213	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. *Vaccine*, **2019**, 37, 3190-3198	4.1	17
212	An Experimental Group A Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. *MBio*, **2019**, 10,	7.8	29
211	Comparison between a new multiplex electrochemiluminescence assay and the WHO reference enzyme-linked immunosorbent assay to measure serum antibodies against pneumococcal serotype-specific polysaccharides. *Vaccine*, **2019**, 37, 2208-2215	4.1	4
210	Health-Related Quality of Life and Emotional Health in X-Linked Carriers of Chronic Granulomatous Disease in the United Kingdom. *Journal of Clinical Immunology*, **2019**, 39, 195-199	5.7	5
209	The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ?. *Lancet Infectious Diseases, The*, **2019**, 19, 453-454	25.5	3
208	Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines - AuthorsPreply. *Lancet Infectious Diseases, The*, **2019**, 19, 693-694	25.5	
207	Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. *Lancet Infectious Diseases, The*, **2019**, 19, 156-164	25.5	8
206	A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Challenge. *Infection and Immunity*, **2019**, 87,	3.7	13
205	Effect of Maternally Derived Anti-protein and Anticapsular IgG Antibodies on the Rate of Acquisition of Nasopharyngeal Carriage of Pneumococcus in Newborns. *Clinical Infectious Diseases*, **2018**, 66, 121-130	11.6	6
204	A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. *Journal of Rheumatology*, **2018**, 45, 733-744	4.1	50
203	Neonatal Immunization: Rationale, Current State, and Future Prospects. *Frontiers in Immunology*, **2018**, 9, 532	8.4	29
202	Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I. *Vaccine*, **2018**, 36, 4944-4951	4.1	4
201	Development of an opsonophagocytic killing assay for group a streptococcus. *Vaccine*, **2018**, 36, 3756-3763	4.1	15
200	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. *Lancet Infectious Diseases, The*, **2018**, 18, 171-179	25.5	70
199	Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation. *Scientific Reports*, **2018**, 8, 15376	4.9	2
198	Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. *Biologicals*, **2018**, 56, 29-38	1.8	13

197	Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam. *Human Vaccines and Immunotherapeutics*, **2018**, 14, 1939-1947	4.4	12
196	Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule - AuthorsPreply. *Lancet Infectious Diseases, The*, **2018**, 18, 382-383	25.5	1
195	Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae. *Vaccine*, **2018**, 36, 4255-4264	4.1	5
194	Assignment of Opsonic Values to Pneumococcal Reference Serum 007sp for Use in Opsonophagocytic Assays for 13 Serotypes. *Vaccine Journal*, **2017**, 24,		19
193	Raised Serum IL-8 Levels Are Associated with Excessive Fatigue in Female Carriers of X-Linked Chronic Granulomatous Disease in the UK. *Journal of Clinical Immunology*, **2017**, 37, 279-281	5.7	5
192	Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy. *Pediatric Infectious Disease Journal*, **2017**, 36, 1186-1192	3.4	24
191	Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 628-630.e6	11.5	36
190	An Uncommon Site of Colonization Leading to Recurrent Pneumococcal Disease. *Open Forum Infectious Diseases*, **2017**, 4, ofw257	1	4
189	The indirect effect of pneumococcal conjugate vaccine. *The Lancet Global Health*, **2017**, 5, e6-e7	13.6	2
188	A longitudinal study of the infant nasopharyngeal microbiota: The effects of age, illness and antibiotic use in a cohort of South East Asian children. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005975	4.8	31
187	Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. *MAbs*, **2017**, 9, 1282-1296	6.6	29
186	Assignment of Weight-Based Antibody Units for Four Additional Serotypes to a Human Antipneumococcal Standard Reference Serum, 007sp. *Vaccine Journal*, **2017**, 24,		3
185	Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage. *Vaccine*, **2017**, 35, 4652-4657	4.1	17
184	Natural IgM antibodies in the immune defence against neoehrlichiosis. *Infectious Diseases*, **2017**, 49, 809-816	3.1	4
183	Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. *Vaccine*, **2017**, 35, 5186-5193	4.1	10
182	Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial. *Vaccine*, **2017**, 35, 7181-7186	4.1	20
181	Naturally Acquired Human Immunity to Pneumococcus Is Dependent on Antibody to Protein Antigens. *PLoS Pathogens*, **2017**, 13, e1006137	7.6	57
180	Genome-wide identification of lineage and locus specific variation associated with pneumococcal carriage duration. *ELife*, **2017**, 6,	8.9	50

179	Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing Isolates. *Journal of Infectious Diseases*, **2017**, 215, 713-722	7	17
178	Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population. *Arthritis Care and Research*, **2016**, 68, 853-60	4.7	13
177	Maternal and neonatal pneumococcal vaccination - where are we now?. *Expert Review of Vaccines*, **2016**, 15, 1305-17	5.2	12
176	Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and WaldenstromB Macroglobulinemia. *Vaccine Journal*, **2016**, 23, 379-85		16
175	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. *Pediatric Infectious Disease Journal*, **2016**, 35, 787-93	3.4	13
174	Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. *The Lancet Global Health*, **2016**, 4, e185-94	13.6	34
173	B-cell development and pneumococcal immunity in vertically acquired HIV infection. *Aids*, **2016**, 30, 1867-76	3.5	2
172	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. *Pediatrics*, **2016**, 138,	7.4	18
171	Climate induces seasonality in pneumococcal transmission. *Scientific Reports*, **2015**, 5, 11344	4.9	31
170	Genomics Reveals the Worldwide Distribution of Multidrug-Resistant Serotype 6E Pneumococci. *Journal of Clinical Microbiology*, **2015**, 53, 2271-85	9.7	21
169	Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide After HIV-associated Invasive Pneumococcal Disease. *Journal of Infectious Diseases*, **2015**, 212, 1093-9	7	4
168	Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. *Clinical Infectious Diseases*, **2015**, 61, 1637-44	11.6	310
167	Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp. *Vaccine Journal*, **2015**, 22, 1154-9		8
166	Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets. *Infection and Immunity*, **2015**, 83, 2889-96	3.7	5
165	Persistence of IgG antibody following routine infant immunization with the 7-valent pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*, **2015**, 34, e138-42	3.4	3
164	The influence of paediatric HIV infection on circulating B cell subsets and CXCR5(+) T helper cells. *Clinical and Experimental Immunology*, **2015**, 181, 110-7	6.2	17
163	The Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage: A Meta-regression Model. *Pediatric Infectious Disease Journal*, **2015**, 34, 858-64	3.4	32
162	Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia. *Emerging Infectious Diseases*, **2015**, 21, 2080-3	10.2	13

161	The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. *PLoS Medicine*, **2015**, 12, e1001839	11.6	42
160	Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies. *Vaccine Journal*, **2015**, 22, 404-12		7
159	Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. *Vaccine*, **2015**, 33, 6675-83	4.1	14
158	Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. *Vaccine*, **2015**, 33, 648-55	4.1	13
157	Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. *PLoS ONE*, **2015**, 10, e0144739	3.7	27
156	Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial. *Vaccine*, **2014**, 32, 5266-70	4.1	17
155	Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infectious Diseases, The*, **2014**, 14, 839-46	25.5	330
154	Dense genomic sampling identifies highways of pneumococcal recombination. *Nature Genetics*, **2014**, 46, 305-309	36.3	269
153	Recent advances in chronic granulomatous disease. *Journal of Infection*, **2014**, 69 Suppl 1, S32-5	18.9	29
152	Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands. *Frontiers in Pharmacology*, **2014**, 5, 8	5.6	17
151	Comprehensive identification of single nucleotide polymorphisms associated with beta-lactam resistance within pneumococcal mosaic genes. *PLoS Genetics*, **2014**, 10, e1004547	6	132
150	Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S161-71	3.4	71
149	Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S107-8	3.4	4
148	Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. *Aids*, **2014**, 28, 2033-43	3.5	21
147	Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S182-7	3.4	10
146	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S140-51	3.4	75
145	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S119-29	3.4	41
144	Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S172-81	3.4	58

143	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S152-60	3.4	72
142	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S109-18	3.4	76
141	The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S130-9	3.4	23
140	Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. *PLoS ONE*, **2014**, 9, e85459	3.7	31
139	Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. *Journal of Clinical Immunology*, **2013**, 33, 8-13	5.7	56
138	Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1150-5	11.5	81
137	Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. *Vaccine*, **2013**, 31, 1453-7	4.1	30
136	Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease. *Journal of Clinical Immunology*, **2013**, 33, 1276-84	5.7	55
135	Nonsense in Public Places: Songs of Black Vocal Rhythm and Blues or Doo-Wop. *Journal of Aesthetics and Art Criticism*, **2013**, 71, 101-110	0.3	
134	Umhlaba 1913–2013. *Social Dynamics*, **2013**, 39, 327-352	0.2	
133	Infection risk in ANCA-associated vasculitis. *Presse Medicale*, **2013**, 42, 665-666	2.2	
132	Colonisation endpoints in Streptococcus pneumoniae vaccine trials. *Vaccine*, **2013**, 32, 153-8	4.1	39
131	Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose. *Vaccine*, **2013**, 31, 5834-42	4.1	4
130	Design questions for Streptococcus pneumoniae vaccine trials with a colonisation endpoint. *Vaccine*, **2013**, 32, 159-64	4.1	14
129	Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 855-64	10.2	110
128	Cognitive ability in children with chronic granulomatous disease: a comparison of those managed conservatively with those who have undergone hematopoietic stem cell transplant. *Neuropediatrics* , **2013**, 44, 230-2	1.6	9
127	The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination. *Proceedings of the Royal Society B: Biological Sciences*, **2013**, 280, 20131939	4.4	24
126	Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. *Clinical Microbiology and Infection*, **2013**, 19, E551-8	9.5	42

125	High rates of pneumonia in children under two years of age in a South East Asian refugee population. *PLoS ONE*, **2013**, 8, e54026	3.7	25
124	Field evaluation of culture plus latex sweep serotyping for detection of multiple pneumococcal serotype colonisation in infants and young children. *PLoS ONE*, **2013**, 8, e67933	3.7	13
123	Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. *PLoS ONE*, **2013**, 8, e74906	3.7	49
122	Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. *PLoS ONE*, **2013**, 8, e51460	3.7	25
121	The fundamental link between pneumococcal carriage and disease. *Expert Review of Vaccines*, **2012**, 11, 841-55	5.2	408
120	Early-life and contemporaneous nutritional and environmental predictors of antibody response to vaccination in young Gambian adults. *Vaccine*, **2012**, 30, 4842-8	4.1	9
119	Assessment of Streptococcus pneumoniae pilus islet-1 prevalence in carried and transmitted isolates from mother-infant pairs on the Thailand-Burma border. *Clinical Microbiology and Infection*, **2012**, 18, 970-5	9.5	15
118	A high burden of respiratory syncytial virus associated pneumonia in children less than two years of age in a South East Asian refugee population. *PLoS ONE*, **2012**, 7, e50100	3.7	9
117	RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. *Infection and Immunity*, **2012**, 80, 451-60	3.7	36
116	Emotional and behavioural difficulties in chronic granulomatous disease. *Archives of Disease in Childhood*, **2012**, 97, 87	2.2	6
115	Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. *Pediatric Infectious Disease Journal*, **2012**, 31, 616-22	3.4	30
114	A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. *PLoS ONE*, **2012**, 7, e38271	3.7	89
113	The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. *Vaccine*, **2011**, 29, 2999-3007	4.1	30
112	Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. *Journal of Clinical Microbiology*, **2011**, 49, 1784-9	9.7	118
111	Establishment of a new human pneumococcal standard reference serum, 007sp. *Vaccine Journal*, **2011**, 18, 1728-36		77
110	Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. *Vaccine Journal*, **2011**, 18, 367-72		19
109	Detection of respiratory viruses by PCR assay of nasopharyngeal swabs stored in skim milk-tryptone-glucose-glycerol transport medium. *Journal of Clinical Microbiology*, **2011**, 49, 2311-3	9.7	11
108	Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgG. *Vaccine Journal*, **2011**, 18, 1744-51		26

107	Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. *Vaccine Journal*, **2011**, 18, 135-42		53
106	Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. *Clinical Infectious Diseases*, **2011**, 53, 663-70	11.6	44
105	The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. *Vaccine*, **2010**, 28, 4763-70	4.1	33
104	Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. *Vaccine*, **2010**, 28, 6915-22	4.1	15
103	Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. *Pediatric Infectious Disease Journal*, **2010**, 29, 401-5	3.4	57
102	Dendritic cell anergy results from endotoxemia in severe malnutrition. *Journal of Immunology*, **2009** , 183, 2818-26	5.3	55
101	Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. *Journal of Immunology*, **2009**, 183, 5622-9	5.3	102
100	CD4 counts decline despite nutritional recovery in HIV-infected Zambian children with severe malnutrition. *Pediatrics*, **2009**, 123, e347-51	7.4	26
99	Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae. *European Journal of Immunology*, **2009**, 39, 1527-35	6.1	7
98	The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. *Clinical Infectious Diseases*, **2009**, 49, 1318-25	11.6	125
97	Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. *Clinical and Experimental Immunology*, **2008**, 151, 51-60	6.2	55
96	Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. *Clinical and Experimental Immunology*, **2008**, 152, 211-8	6.2	173
95	Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells. *Immunology*, **2008**, 125, 469-79	7.8	5
94	Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. *Vaccine*, **2008**, 26, 3719-26	4.1	38
93	Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. *Vaccine*, **2008**, 26, 4434-45	4.1	107
92	Bacteria, polysaccharides, vaccines and boosting: measuring and maintaining population immunity. *Archives of Disease in Childhood*, **2008**, 93, 646-7	2.2	8
91	Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. *Clinical and Experimental Immunology*, **2007**, 148, 79-84	6.2	105
90	Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. *Vaccine Journal*, **2007**, 14, 397-403		14

89	Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. *Vaccine Journal*, **2007**, 14, 1328-33		26
88	Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. *Vaccine Journal*, **2007**, 14, 1362-9		38
87	Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. *Lancet, The*, **2007**, 369, 1440-1451	40	216
86	WHO guidelines for treatment of severe pneumonia AuthorsPreply. *Lancet, The*, **2007**, 370, 385-386	40	0
85	Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. *Lancet Infectious Diseases, The*, **2007**, 7, 597-606	25.5	173
84	Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. *Vaccine Journal*, **2006**, 13, 356-60		105
83	Pneumococcal polysaccharides interact with human dendritic cells. *Infection and Immunity*, **2006**, 74, 1890-5	3.7	30
82	Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. *Journal of Infectious Diseases*, **2006**, 194, 385-90	7	66
81	Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. *Journal of Infectious Diseases*, **2006**, 194, 1745-52	7	128
80	Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. *Vaccine Journal*, **2006**, 13, 165-9		165
79	Reply to Bogaert et al.. *Journal of Infectious Diseases*, **2006**, 194, 1618-1619	7	4
78	Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. *Infection and Immunity*, **2006**, 74, 1025-31	3.7	13
77	Pneumococcal vaccination in developing countries. *Lancet, The*, **2006**, 367, 1880-2	40	142
76	Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. *Pediatric Infectious Disease Journal*, **2006**, 25, 312-9	3.4	130
75	Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. *Tropical Medicine and International Health*, **2006**, 11, 1529-41	2.3	38
74	Probable mother to infant transmission of Pneumocystis jiroveci from an HIV-infected woman to her HIV-uninfected infant. *Aids*, **2005**, 19, 1548-9	3.5	23
73	Chronic granulomatous disease: from genetic defect to clinical presentation. *Advances in Experimental Medicine and Biology*, **2005**, 568, 67-87	3.6	28
72	Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. *Journal of Infectious Diseases*, **2005**, 192, 387-93	7	189

71	Hib IgG persistence following early booster dose. *Archives of Disease in Childhood*, **2005**, 90, 329	2.2	
70	Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, **2004**, 89, F269-71	4.7	22
69	Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. *Vaccine Journal*, **2004**, 11, 1100-4		44
68	Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. *Infection and Immunity*, **2004**, 72, 5383-91	3.7	74
67	Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. *Vaccine Journal*, **2003**, 10, 1019-24		52
66	The nature of colitis in chronic granulomatous disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2003**, 36, 623-31	2.8	60
65	Humoral immunity in children with biliary atresia splenic malformation syndrome. *European Journal of Pediatrics*, **2003**, 162, 539-540	4.1	9
64	Conjugate Hib vaccines. *Lancet, The*, **2003**, 361, 360-1	40	31
63	Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. *Lancet, The*, **2003**, 362, 449-50	40	44
62	Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. *Vaccine*, **2003**, 21, 3265-72	4.1	283
61	Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. *Vaccine Journal*, **2003**, 10, 514-9		251
60	Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. *Infection and Immunity*, **2003**, 71, 5549-55	3.7	84
59	Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). *Journal of Leukocyte Biology*, **2003**, 73, 591-9	6.5	117
58	Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. *Clinical and Experimental Immunology*, **2002**, 128, 118-23	6.2	156
57	Increased expression of interleukin-13 but not interleukin-4 in CD4+ cells from patients with the hyper-IgE syndrome. *Clinical and Experimental Immunology*, **2002**, 128, 532-7	6.2	18
56	A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. *Vox Sanguinis*, **2002**, 83, 17-22	3.1	17
55	Prenatal diagnosis in two families with autosomal, p47(phox)-deficient chronic granulomatous disease due to a novel point mutation in NCF1. *Prenatal Diagnosis*, **2002**, 22, 235-40	3.2	18
54	Current treatment options for chronic granulomatous disease. *Expert Opinion on Pharmacotherapy*, **2002**, 3, 857-63	4	24

53	Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. *Journal of Infectious Diseases*, **2002**, 185, 397-400	7	54
52	Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. *Infection and Immunity*, **2002**, 70, 4946-54	3.7	80
51	Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. *Journal of Infectious Diseases*, **2002**, 186, 1353-7	7	99
50	Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. *Pediatric Infectious Disease Journal*, **2002**, 21, 940-7	3.4	28
49	Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. *Vaccine*, **2002**, 20, 2592-6	4.1	37
48	X-linked lymphoproliferative disease: three atypical cases. *Clinical and Experimental Immunology*, **2001**, 126, 126-30	6.2	45
47	Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. *Infection and Immunity*, **2001**, 69, 1568-73	3.7	281
46	Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. *Journal of Infectious Diseases*, **2001**, 184, 1617-20	7	74
45	Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. *Journal of Infectious Diseases*, **2001**, 184, 377-80	7	65
44	Colitis in chronic granulomatous disease. *Archives of Disease in Childhood*, **2001**, 84, 147-51	2.2	106
43	Hematopoietic-cell transplantation for chronic granulomatous disease. *New England Journal of Medicine*, **2001**, 345, 377-8	59.2	4
42	Immune response and host-pathogen interactions. *Methods in Molecular Medicine*, **2001**, 66, 23-39		1
41	Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. *Journal of Infectious Diseases*, **2001**, 183, 160-3	7	200
40	Clinical relevance of lower Hib response in DTPa-based combination vaccines. *Vaccine*, **2001**, 19, 2280-5	4.1	49
39	Immunogenetic analysis of the immune response to pneumococcal polysaccharide. *European Journal of Immunology*, **2000**, 30, 1214-23	6.1	68
38	Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. *European Journal of Immunology*, **2000**, 30, 1691-7	6.1	62
37	Follow up of patients with chronic granulomatous disease diagnosed since 1990. *Clinical and Experimental Immunology*, **2000**, 120, 351-5	6.2	72
36	Preparation of human-mouse heterohybridomas against an immunising antigen. *Journal of Immunological Methods*, **2000**, 246, 187-202	2.5	18

35	An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. *Journal of Clinical Microbiology*, **2000**, 38, 2043-50	9.7	65
34	Immunogenetic analysis of the immune response to pneumococcal polysaccharide **2000**, 30, 1214		1
33	An Analytical Model Applied to a Multicenter Pneumococcal Enzyme-Linked Immunosorbent Assay Study. *Journal of Clinical Microbiology*, **2000**, 38, 2043-2050	9.7	7
32	The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. *Journal of Infectious Diseases*, **1999**, 180, 538-41	7	78
31	Pericardial effusions in two boys with chronic granulomatous disease. *Pediatric Radiology*, **1999**, 29, 820-2	2.8	7
30	Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. *Vaccine*, **1999**, 18, 641-6	4.1	69
29	Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. *Lancet, The*, **1999**, 354, 2063-8	40	186
28	Chorioretinal lesions in patients and carriers of chronic granulomatous disease. *Journal of Pediatrics* , **1999**, 134, 780-3	3.6	75
27	A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. *Vaccine Journal*, **1999**, 6, 581-6		59
26	Antibody response to outer membrane proteins of Moraxella catarrhalis in children with otitis media. *Pediatric Infectious Disease Journal*, **1999**, 18, 982-8	3.4	28
25	Hospital admissions in children due to pneumococcal pneumonia in England. *Journal of Infection*, **1998**, 37, 54-8	18.9	34
24	Measles vaccination and inflammatory bowel disease. *Lancet, The*, **1998**, 351, 755-6	40	9
23	Autism, inflammatory bowel disease, and MMR vaccine. *Lancet, The*, **1998**, 351, 1355-6; author reply 1356	40	2
22	Recent developments in bacterial conjugate vaccines. *Journal of Medical Microbiology*, **1998**, 47, 563-7	3.2	48
21	Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. *Journal of Infectious Diseases*, **1998**, 177, 1112-5	7	193
20	Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). *Journal of Immunological Methods*, **1997**, 205, 67-72	2.5	35
19	Characterisation of an outer membrane protein of Moraxella catarrhalis. *FEMS Immunology and Medical Microbiology*, **1997**, 19, 231-6		15
18	Transfusion associated graft-versus-host disease in DiGeorge syndrome: Index case report with survey of screening procedures and use of irradiated blood components. *Cardiology in the Young*, **1996**, 6, 222-227	1	8

17	Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. *Immunology*, **1996**, 88, 169-73	7.8	33
16	Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. *Archives of Disease in Childhood*, **1996**, 75, 159-61	2.2	21
15	Interchangeability of conjugated Haemophilus influenzae type b vaccines during primary immunisation of infants. *BMJ: British Medical Journal*, **1996**, 312, 817-8		12
14	Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. *Pediatric Infectious Disease Journal*, **1996**, 15, 1097-101	3.4	33
13	Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. *Pediatric Infectious Disease Journal*, **1995**, 14, 129-35	3.4	35
12	The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. *Journal of Immunological Methods*, **1993**, 166, 281-5	2.5	32
11	Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharides of Streptococcus pneumoniae in childhood. *Journal of Infectious Diseases*, **1992**, 166, 632-4	7	33
10	Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. *Journal of Infectious Diseases*, **1990**, 162, 1128-35	7	59
9	An enzyme-linked immunosorbent assay for the determination of human IgG subclass antibodies directed against Branhamella catarrhalis. *Journal of Immunological Methods*, **1990**, 128, 219-25	2.5	19
8	The Immunobiology of Polysaccharide and Conjugate Vaccines67-82		5
7	Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam: a dynamic transmission model		1
6	Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2		2
5	Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs		2
4	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2		2
3	Extremely high SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK		6
2	A Population-Based Threshold of Protection for COVID-19 Vaccines		4
1	Correlates of protection against SARS - CoV -2 infection and COVID-19 disease. *Immunological Reviews*,	11.3	6